NCT01526499Unknown2 期
Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
The purpose of this study is to evaluate the role of metronomic cyclophosphamide in addition to docetaxel in first line therapy in metastatic breast cancer.
详细描述
Metronomic chemotherapy has been considered as an effective strategy for metastatic breast cancer. This trial is designed to evaluate the role of metronomic cyclophosphamide in addition to docetaxel in first line therapy in metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females with age between 18 and 70 years old
- •ECOG performance between 0-1
- •Life expectancy more than 3 months
- •Histological proven unresectable recurrent or advanced breast cancer
- •No previous chemotherapy for metastatic breast cancer;suitable for monotherapy (Neoadjuvant or adjuvant docetaxel should be completed at least one year).
- •At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST1.1)
- •No anticancer therapy within 4 weeks
- •Adequate hematologic, hepatic, and renal function,No serious medical history of heart, lung, liver and kidney
- •Provision of written informed consent prior to any study specific procedures
排除标准
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
- •Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study
- •Treatment with an investigational product within 4 weeks before the first treatment
- •Symptomatic central nervous system metastases
- •Other active malignancies (including other hematologic malignancies) or other malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
- •Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
- •Uncontrolled serious infection
- •Patients with bad compliance
研究组 & 干预措施
TC
Experimental
Docetaxel plus Cyclophosphamide
干预措施: Docetaxel and Cyclophosphamide (TC) (Drug)
T
Active Comparator
Docetaxel
干预措施: Docetaxel (T) (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: 6 weeks
次要结局
- Biomarker serum VEGF level(6 weeks)
- Biomarker immuno-marker(6 weeks)
- Efficacy Overall Response Rate(6 weeks)
- Efficacy Overall Survival(6 weeks)
- Safety(6 weeks)
- genetic polymorphisms(6 weeks)
研究者
yanfei Liu
principal investigator
Fudan University
研究点 (1)
Loading locations...
相似试验
未知
2 期
A Phase II study of docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancerBreast cancerJPRN-UMIN000000493Japan East Cancer Center Breast Cancer Consortium50
已完成
2 期
Feasibility study of TC(docetaxel+Cyclophosphamide)as adjuvant chemotherapy for intermediate risk primary breast cancer with HER2-negative and ER-positive tumor(KBC-SG 0803)Breast cancerJPRN-UMIN000001582Kyushu Breast Cancer Study Group102
已完成
不适用
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and CapecitabineBreast CancerNCT00156312University of Michigan Rogel Cancer Center25
招募中
2 期
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast CarcinomaNCT06042569City of Hope Medical Center174
已完成
1 期
Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly PaclitaxelCancerNCT01374620Centre Oscar Lambret28